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ABSTRACT: Background: Gait disturbance is an early,
disabling feature of Parkinson’s disease (PD) that is typi-
cally refractory to dopaminergic medication. The cortical
cholinergic system, originating in the nucleus basalis of
Meynert of the basal forebrain, has been implicated. How-
ever, it is not known if degeneration in this region relates
to a worsening of disease-specific gait impairment.
Objective: To evaluate associations between sub-
regional cholinergic basal forebrain volumes and longitu-
dinal progression of gait impairment in PD.
Methods: 99 PD participants and 47 control participants
completed gait assessments via an instrumented walk-
way during 2 minutes of continuous walking, at baseline
and for up to 3 years, from which 16 spatiotemporal
characteristics were derived. Sub-regional cholinergic
basal forebrain volumes were measured at baseline via
MRI and a regional map derived from post-mortem his-
tology. Univariate analyses evaluated cross-sectional
associations between sub-regional volumes and gait.
Linear mixed-effects models assessed whether volumes
predicted longitudinal gait changes.
Results: There were no cross-sectional, age-
independent relationships between sub-regional volumes
and gait. However, nucleus basalis of Meynert volumes
predicted longitudinal gait changes unique to
PD. Specifically, smaller nucleus basalis of Meynert vol-
ume predicted increasing step time variability (P = 0.019)
and shortening swing time (P = 0.015); smaller posterior
nucleus portions predicted shortening step length
(P = 0.007) and increasing step time variability (P = 0.041).
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Conclusions: This is the first study to demonstrate that
degeneration of the cortical cholinergic system predicts
longitudinal progression of gait impairments in
PD. Measures of this degeneration may therefore provide
a novel biomarker for identifying future mobility loss and
falls. © 2020 The Authors. Movement Disorders
published by Wiley Periodicals LLC on behalf of Interna-
tional Parkinson and Movement Disorder Society.
Key Words: Parkinson’s disease; structural MRI; gait;
NBM; acetylcholine
Gait impairment is a common, debilitating feature of
Parkinson’s disease (PD) that manifests in early and
even prodromal disease stages.1-3 It impacts quality of
life4 and is associated with increased falls risk,5 cogni-
tive decline,6 and reduced activity.7 Gait can be
described through quantitatively measured characteris-
tics8 reflecting selective gait alterations in response to
ageing and disease.9,10
Dopaminergic medications can immediately improve
some aspects of PD gait,11-13 yet some characteristics
continue to worsen over time despite optimal dopami-
nergic treatment.10 Current understanding of the neuro-
anatomical and functional substrates underpinning gait
impairment is poor;14 establishing the non-
dopaminergic neurotransmitter systems involved in gait
would enable development of intervention strategies
that more effectively target gait decline in early PD.
Emerging evidence suggests the cholinergic system is
involved in PD gait control.15,16 Reduced thalamic cho-
linergic innervation, originating from the
pedunculopontine nucleus-laterodorsal tegmental com-
plex (PPN), has been associated with falls,17 freezing of
gait,18 and balance disturbance19 in PD. Furthermore,
reduced PPN structural integrity has been associated
with postural instability and gait disturbance in pri-
mates20 and PD.21
Cortical cholinergic denervation may also relate to
PD gait impairment.15 Slower walking speed and
shorter step length have been linked to reduced short-
latency afferent inhibition (SAI),22 indicative of less cor-
tical cholinergic activity. Slower walking speed has also
been associated with cortical cholinergic denervation
and not thalamic cholinergic denervation.23-25 The
nucleus basalis of Meynert (NBM), within the choliner-
gic basal forebrain (cBF), provides the major choliner-
gic input to the cortex. This region has been notably
linked to cognitive changes seen in age and age-related
diseases.26-29 Taken with the well-established relation-
ship between discrete gait impairments and cognitive
impairment in PD,6,30 this implies that NBM degenera-
tion may be implicated in gait impairments. Indeed,
recent work has identified a cross-sectional association
between NBM integrity and fast walking speed
10 years after PD diagnosis.31
Although cross-sectional studies provide insights, lon-
gitudinal studies are needed to understand the neural
mechanisms contributing to gait decline and to identify
biomarkers to monitor and predict these changes with
progressing disease, within a timeframe where interven-
tions would be most beneficial. We have shown that
cerebrospinal fluid (CSF) β-amyloid 1–42 levels, poten-
tially linked to cortical cholinergic neurotransmission,32
predict gait decline in PD.10 As cBF Lewy body aggre-
gates and neuronal losses occur early in disease,17 cBF
volumetric measures may provide early biomarkers of
gait decline. Recent work has identified that NBM vol-
umes quantified in very early disease can predict future
cognitive decline in PD.26,28 However, whether these
volumetric measures can also predict gait decline has
not been investigated.
This study aimed to investigate the cortical choliner-
gic underpinnings of PD gait impairment. Using stereo-
tactic mapping of the cBF, specific aims were to;
(1) explore the relationship of sub-regional cBF vol-
umes with gait, and (2) assess the ability of sub-regional
cBF volumes to predict disease-specific progression of
gait impairments over 3 years. We hypothesized that
NBM volumes, rather than an adjacent cBF region that
projects to the hippocampus, would most strongly
relate to PD gait. Additionally, characteristics related to
gait pace and variability, which are strongly linked with




Participants with idiopathic PD and age-matched
controls were recruited to the Incidence of Cognitive
Impairment in Cohorts with Longitudinal Evaluation-
PD study (ICICLE-PD), with optional additional
recruitment into the collaborative ICICLE-GAIT study.
Recruitment was conducted between June 2009 and
December 2011.33,34 Exclusion criteria included cogni-
tive impairment (Mini-Mental State Examination
[MMSE] ≤24), diagnosis of parkinsonian disorders
other than PD and poor command of the English lan-
guage. Clinical and gait assessments were completed at
three sessions: baseline, 18 months, and 36 months.
MRI was completed at baseline. Idiopathic PD was
diagnosed according to the Queen Square Brain Bank
criteria35; diagnoses were reviewed at each assessment
to reduce misdiagnosis risk. Participants were tested
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“on” dopaminergic medication for all assessments
(1 hour after medication).
Participants within the current analysis were those
with baseline MRI and gait data available. Baseline
assessments were a median of 5.1 months after diagno-
sis in this restricted cohort of 100 PD and 47 control
participants. This time elapsed from diagnosis to base-
line assessment is comparable to some previous studies
of gait impairment in PD (mean of 536 and 7 months37
from diagnosis in previous cohort studies), although the
severity of motor symptoms (mean MDS-UPDRS III) of
our cohort was higher (25 compared to 16 and
21, respectively). Other cohorts have assessed PD par-
ticipants with a longer disease duration.38-40 The mean
age at baseline in this study (66.5 years) compares well
with these other cohorts (mean baseline age of
62–68 years across studies).
One PD brain image was excluded after manual
image inspection; therefore, 99 PD participants had
data available for use. The study was approved by the
Newcastle and North Tyneside Research and Ethics
Committee.
Clinical Assessments
Age, sex, height, mass, years of education, disease
duration, acetylcholinesterase (AChE) inhibitor pre-
scription, and depression (Geriatric Depression Scale
[GDS-15]) were recorded. The National Adult Reading
Test (NART) assessed premorbid intelligence at base-
line. Global cognition was assessed through the MMSE
and Montreal Cognitive Assessment (MoCA). PD-
specific motor severity was assessed through the Move-
ment Disorders Society Unified Parkinson’s Disease
Rating Scale part three (MDS-UPDRS III), from which
Hoehn & Yahr stage (H&Y) was derived. Levodopa
(L-dopa) equivalent daily dose (LEDD) was
calculated.41
Gait Assessments
Participants walked at their self-selected pace for
2 minutes around a 25-m oval circuit that included a
7-m long instrumented walkway (Platinum model
GAITRite, CIR Systems, Franklin, NJ). At least 40 steps
were completed over the walkway per participant to
ensure robust measurement of gait variability.42 Gait
outcomes were derived and quantified according to an
a priori model developed for older adults and validated
in PD,8 that describes 16 discrete gait characteristics
within five domains. Methods to calculate the gait vari-
ables have been described previously.42
MRI Acquisition
MRI acquisition was performed using a 3T Philips
Intera Achieva scanner (Philips Medical Systems, Eind-
hoven, The Netherlands). A magnetization-prepared
rapid acquisition gradient echo (MP-RAGE) T1-
weighted sequence produced high-resolution structural
images with the following parameters: repetition
time = 9.6 ms, echo time = 4.6 ms, flip angle = 8,
SENSE factor = 2, field of view = 240 × 240 mm, voxel
size = 1.5 × 1.5 × 1.5 mm3, acquisition time =
4 minutes; 150 sagittal slices (slice thickness = 1.2 mm)
were taken.
cBF Stereotactic Map
Stereotactic mapping of cBF nuclei was used to create
the cBF map, as described by Kilimann et al.43 Briefly,
the map was derived from a brain specimen of a
56-year-old male who died from myocardial infarction.
This brain specimen underwent histological preparation
and post-mortem MRI scans, both in situ and after the
brain was dehydrated for histological preparation.
Mesulam’s nomenclature44 was followed to identify
cholinergic nuclei on digital pictures of stained brain
slices, these were manually transferred into
corresponding MR slices of the dehydrated brain. The
MRI scan of the dehydrated brain was transformed into
the space of the post-mortem in situ scan, using an ini-
tial 12-parameter affine transformation followed by a
high-dimensional nonlinear registration between the
two scans.45 This was transferred to Montreal Neuro-
logical Institute (MNI) standard space to enable use of
the high-dimensional DARTEL (diffeomorphic ana-
tomic registration using exponentiated lie algebra) reg-
istration method.46 The final stereotactic map
distinguishes different cBF subdivisions, including cho-
linergic cell clusters corresponding to the medial sep-
tum, vertical and horizontal limb of the diagonal band,
and the NBM.
Image Pre-Processing
T1-weighted MRI scans were automatically seg-
mented into gray matter (GM), white matter, and CSF
partitions using the segmentation routine of the VBM8
toolbox (http://dbm.neuro.uni-jena.de/wordpress/vbm/
download/) running under SPM12 (http://www.fil.ion.
ucl.ac.uk/spm/software/spm12/). Each participant’s
resultant gray and white matter partitions were regis-
tered to MNI space using DARTEL.46 GM segments
were warped using individual flow fields resulting from
DARTEL registration. Voxel values were modulated
for volumetric changes introduced by high-dimensional
normalization, enabling for total GM volume before
warping to be preserved. Pre-processed GM maps were
visually inspected by one of three authors (J.W.,
C.E.C., and/or N.J.R.) for segmentation and registra-
tion accuracy. One PD participant did not pass inspec-
tion and their data was removed.
Region-specific cBF GM volumes were calculated as
means of the total modulated GM voxel values within
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respective region-of-interest masks in template space.
These volumes and global GM were normalized using
regression by total intracranial volume (TIV, sum of
total GM, white matter, and CSF volumes as a proxy
for head size). Following previous PD literature using
this cBF mask,26 regions-of-interest selected for analysis
were: (1) a combination of the medial septum (Ch1)
and vertical limb of the diagonal band (Ch2), (2) the
NBM (Ch4), and (3) a posterior NBM subdivision
(Ch4p) (Fig. 1). TIV-normalized global GM volumes
were additionally extracted and included as con-
founders in analyses to confirm that associations with
cBF volumes were not explained by overall GM
atrophy.
Statistical Analysis
Analyses were conducted using SPSS (IBM Corp.
V.24, USA) and R software (R Foundation for Statisti-
cal Computing, V3.5.2, Austria). The distribution of
continuous variables was tested for normality through
Kolmogorov–Smirnov tests and boxplot and histogram
inspections.
Clinical Comparisons
Student’s t-tests, Mann–Whitney U tests, or χ2 tests
examined baseline clinical characteristic differences
between control and PD participants and, within the
PD group, between those that did (“completers”) and
did not (“non-completers”) complete gait assessment at
36 months. Paired t-tests or Wilcoxon signed-rank tests
assessed differences in baseline and final assessments of
clinical characteristics within diagnostic groups.
Baseline Gait and cBF Volumes
One-way analysis of covariance (ANCOVA), age and
sex corrected, separately assessed differences in baseline
gait and sub-regional cBF volumes between control and
PD participants, and between PD completers and non-
completers. Pearson’s correlation and Pearson’s partial
correlation, age and sex controlled, tested within-group
associations between baseline gait and cBF volumes.
Because of substantial skewness, gait asymmetry data
were square root-transformed and temporal variability
data log transformed for cross-sectional analyses.
Gait Change Over 3 Years
Linear mixed-effects models (LMEM; R, “lme4”47
and “lmerTest”48) separately modeled change in each
gait characteristic over 3 years. Although some partici-
pants withdrew or were lost to follow up across the
36-month study period, all participants with at least
two gait assessments were considered in longitudinal
analyses; LMEM can appropriately estimate regression
coefficients despite drop-out of this nature.49 This
approach can effectively handle the hierarchical nature
of longitudinal, repeated-measures data, without the
need to remove participants with missing data. Random
slope models gave each participant a unique intercept
and slope, allowing for correlation between intercept
and slope. Baseline age and sex were included as fixed
FIG. 1. Cholinergic basal forebrain regions of interest. (Slices from left to right are coronal slices 9, 6, 3, and −8, as demonstrated in the top row. In the
bottom row, the Ch1-2 region of interest is demarcated in the first and second images, corresponding to the medial septum and vertical limb of the
diagonal band; the Ch4 region of interest, corresponding to the NBM, is highlighted in the second and third images; the Ch4p region of interest,
corresponding to the posterior NBM, is shown in the fourth image.) [Color figure can be viewed at wileyonlinelibrary.com]
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effects, and model fit was assessed by likelihood ratio
tests.
Changes in each gait characteristic over time were
separately modeled within each group. Next, in the full
sample, the interaction between group and time was
additionally modeled to assess group differences in gait
change. The effects of changes in L-dopa medication
over time on gait change were assessed through inspec-
tion of the interaction between LEDD and time.
cBF Volumes as Predictors of Gait Change
Gait characteristics identified as significantly chang-
ing over time in PD, and where change was different
from change in controls, were selected for further anal-
ysis. LMEM determined the predictive utility of base-
line cBF volumes for future gait changes in PD
participants. Specifically, the interaction between cBF
volumes and time was modeled with adjustment for
baseline age, sex, and TIV-normalized whole brain GM
volumes as fixed effects. Sub-regional volumes were
included in separate models.
Multiple Comparisons
Group comparisons of clinical and gait characteris-
tics, and significant changes in gait, were considered
significant at P < 0.05, uncorrected. This allowed us to
restrict subsequent analyses to gait characteristics, with
exploratory-level evidence, that are affected by PD. The
NBM (Ch4) has previously been implicated in PD
degeneration26, results for this region were considered
significant at P < 0.05. Posterior NBM (Ch4p), the
medial septum, and vertical limb of the diagonal band
(Ch1-2) regions-of-interest were Benjamini-Hochberg
corrected for multiple comparisons across the two
regions in PD. There were no region-specific predictions
in control participants, therefore Benjamini-Hochberg
corrections were applied across the three cBF sub-
regions. Non-corrected P values are reported.
Results
Participants
A total of 127 PD and 93 control participants con-
sented to both studies (Supplementary Figure S1). After
exclusions, 99 PD and 47 control participants had base-
line imaging and gait data available. At 18 months,
89 (90%) PD participants and 37 (79%) control partic-
ipants completed gait assessment; at 36 months,
69 (70%) PD and 35 (74%) control participants
attended. A total of 67 (68%) PD and 33 (70%) con-
trol participants attended all assessments; 91 (92%) PD
and 39 (83%) control participants attended at least two
gait assessments and were therefore considered within
longitudinal evaluations. The mean time to baseline
assessment from PD diagnosis was 6 months and from
the first subjective motor symptom was 27 months.
Group Comparisons
At baseline, PD and control groups were age and sex
matched, with no significant differences in height, mass,
years of education, or NART score (Table 1). PD par-
ticipants had greater cognitive impairment and depres-
sion scores (MMSE; U = 1673, P = 0.004: MoCA;
U = 1234, P < 0.001: GDS-15; U = 1099, P < 0.001). A
total of 23% of PD participants were H&Y stage I at
baseline, 59% were H&Y stage II, and 18% were
H&Y stage III at baseline. At baseline, 89 (90%) PD
participants were on dopaminergic medication; no par-
ticipants were on AChE inhibitors. A total of 12 of
16 gait characteristics demonstrated greater impairment
in PD than controls (Supplementary Figure S2). There
were no differences between PD and control groups in
any sub-regional cBF volume (posterior NBM [Ch4p]:
F1,142 = 1.17, P = 0.282; NBM [Ch4]: F1,142 = 3.35,
P = 0.069; medial septum and vertical limb of the
diagonal band [Ch1-2]: F1,142 = 0.88, P = 0.351). PD
completers were not significantly different from non-
completers for any clinical, gait, or imaging measure at
baseline (Supplementary Table S1, Appendix S1).
Baseline Associations Between Gait and cBF
Volumes
In PD only, greater baseline step velocity and step
length were correlated bivariately with larger volumes
of all cBF sub-regions (step velocity: jrj > 0.20, P < 0.04
in all sub-regions; step length: jrj > 0.23, P < 0.02 in all
sub-regions, Supplementary Table S2, Appendix S1).
After adjusting for age and sex within partial correla-
tions, associations were no longer significant (jrj < 0.1,
P > 0.05 in all sub-regions, Supplementary Table S3,
Appendix S1).
Longitudinal Changes in Clinical and Gait
Characteristics
Over 3 years, PD motor severity and LEDD increased
(P < 0.001, Supplementary Table S4, Appendix S1).
MMSE, but not MoCA, score worsened over three
years in PD only (P = 0.034); depression did not signifi-
cantly change in either group. Two PD participants
were taking AChE inhibitors at 18 months and three
were at 36 months.
Table 2 presents modeled change in each gait charac-
teristic for PD and control participants, and the group–
time interactions for each characteristic. Over
36 months, 5 of 16 characteristics declined significantly
in PD; change was significantly different from change in
controls for four of these (Supplementary Figure S3).
Step length shortened by 8 mm per year, P = 0.001;
step time variability increased by 0.9 ms per year,
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P = 0.026; step length variability increased by 1.4 mm
per year, P < 0.001; and swing time shortened by
2.8 ms per year, P = 0.003. Although step time changed
significantly over 36 months in PD (P = 0.011), change
was not statistically different from controls (P = 0.228).
As previously identified in the ICICLE cohort,10 change
in LEDD over time was not associated with longitudi-
nal gait change for any gait characteristic except step
width variability (data not shown). LEDD has, there-
fore, not been included in any subsequent analyses
involving gait change.
cBF Volumes as Predictors of Gait Decline
Table 3 summarizes the baseline cBF volume pre-
dictors of PD gait change. Smaller posterior NBM
(Ch4p) volumes predicted greater step length short-
ening (β = 0.098, P = 0.007) and greater step time
variability increase (β = −14.47, P = 0.019) over
36 months; the inclusion of posterior NBM volume
into models improved model fit (χ2 = 7.77,
P = 0.021; χ2 = 6.02, P = 0.049, respectively).
Smaller NBM (Ch4) volumes also predicted greater
step time variability increase (β = −17.20, P = 0.041),
whereas larger NBM volumes predicted greater
swing time shortening (β = −47.88, P = 0.015); NBM
volume inclusion into models improved model fit
(χ2 = 6.86, P = 0.032; χ2 = 6.85, P = 0.033, respec-
tively). To illustrate findings, correlations between
sub-regional cBF volumes and change in gait per year
for individuals, as derived from individual modeled
trajectories of change, are plotted (Fig. 2).
TABLE 1. Clinical gait and cBF characteristics of participants at baseline
Characteristic Parkinson’s disease Controls Statistic, P value
Clinical assessments
N 99 47 –
Age, years 66.53 (10.69) 65.82 (8.02) t = −0.45, P = 0.683
Sex, malesa 66 (67) 29 (62) χ2 = 0.35, P = 0.557
Height, m 1.70 (0.08) 1.71 (0.10) t = 0.87, P = 0.386
Mass, kg 78.93 (15.12) 79.53 (13.05) t = 0.23, P = 0.817
Education, years 13.4 (4.0) 13.8 (3.7) U = 2197, P = 0.584
NART 115.7 (10.3) 117.7 (7.9) U = 2152, P = 0.586
MoCA 25.2 (3.6) 27.7 (2.0) U = 1234, P < 0.001*
MMSE 28.7 (1.3) 29.3 (0.9) U = 1673, P = 0.004*
GDS-15 2.6 (2.2) 0.9 (1.2) U = 1099, P < 0.001*
MDS-UPDRS III 25.2 (10.2) – –
H&Y Stagea 23 I (23), 58 II (59), 18 III (18) – –
Disease duration, months 6.5 (4.8) – –
LEDD (mg/day) 171 (129) – –
Gait assessments
Step velocity, ms−1 1.13 (0.21) 1.29 (0.14) F(1,142) = 24.3, P < 0.001*
Step length, m 0.63 (0.10) 0.69 (0.07) F(1,142) = 19.6, P < 0.001*
Swing time var, ms 17.71 (6.03) 13.92 (3.52) F(1,142) = 16.9, P < 0.001*
Step time var, ms 19.04 (6.41) 14.97 (4.17) F(1,142) = 17.3, P < 0.001*
Stance time var, ms 23.26 (9.74) 17.48 (5.46) F(1,142) = 16.3, P < 0.001*
Step velocity var, ms−1 0.05 (0.02) 0.05 (0.01) F(1,142) = 2.3, P = 0.103
Step length var, m 0.02 (0.01) 0.02 (0.01) F(1,142) = 7.1, P = 0.008*
Step time, ms 563.98 (46.29) 537.82 (45.15) F(1,142) = 9.6, P = 0.002*
Swing time, ms 394.28 (32.95) 386.06 (33.80) F(1,142) = 2.0, P = 0.157
Stance time, ms 734.10 (77.78) 690.73 (62.26) F(1,142) = 10.9, P = 0.001*
Step time asy, ms 20.02 (20.28) 11.44 (9.05) F(1,142) = 7.6, P = 0.007*
Swing time asy, ms 16.06 (15.48) 8.47 (7.89) F(1,142) = 12.0, P = 0.001*
Stance time asy, ms 15.49 (14.95) 8.95 (8.37) F(1,142) = 9.45, P = 0.003*
Step length asy, m 0.02 (0.02) 0.02 (0.02) F(1,142) = 0.5, P = 0.487
Step width, m 0.09 (0.03) 0.09 (0.02) F(1,142) = 0.4, P = 0.847
Step width var, m 0.02 (0.01) 0.02 (0.01) F(1,142) = 7.7, P = 0.006*
cBF assessments
TIV normalized Ch4p volume, mm3 −0.004 (0.066) 0.008 (0.055) F1,142 = 1.17, P = 0.282
TIV normalized Ch4 volume, mm3 −0.005 (0.049) 0.010 (0.044) F1,142 = 3.35, P = 0.069;
TIV normalized Ch1-2 volume, mm3 −0.003 (0.056) 0.007 (0.052) F1,142 = 0.88, P = 0.351
All figures are mean (standard deviation) except a where figures are n (%). At baseline, n = 6 did not complete MoCA and n = 1 did not complete NART in the
Parkinson’s disease group. Significant differences are in bold, denoted by *.
Abbreviations: GDS-15, Geriatric Depression Scale; NART, National Adult Reading Test; MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental State Exam-
ination; MDS-UPDRS III, Movement Disorders Society Unified Parkinson’s disease rating scale part three; H&Y, Hoehn and Yahr; LEDD, Levodopa equivalent
daily dose; var, variability (standard deviation); asy, asymmetry; cBF, cholinergic basal forebrain; TIV, total intracranial volume (note cBF volumes are TIV-normal-
ized using analysis of covariance).
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Discussion
To our knowledge, this is the first study to assess the
relationship between cBF volumes and PD gait dysfunc-
tion longitudinally. Assessments were completed in a
relatively homogeneous PD cohort and well-matched
controls, enabling precise modeling of disease-specific
gait changes. Assessments were conducted at a time
where intervention strategies may be most effective. We
found no age-independent cross-sectional relationships
between cBF volumes and gait. However, NBM vol-
umes uniquely predicted future disease-specific gait
decline. In addition, gait pace and variability character-
istics were most closely linked with NBM degeneration.
These findings improve understanding of the cortical
cholinergic underpinnings of gait impairment and imply
that NBM volumetric measurement may serve as a pre-
dictive biomarker for PD gait changes.
Cross-Sectional Associations Are Mediated
by Age
There was limited association between gait variables
and sub-regional cBF volumes in both PD and control
groups at baseline, with only step velocity and step
length identified in PD. However, this finding did not
survive control for age and sex. Ray et al26 also found
no cross-sectional relationships between cBF volumes
and cognitive scores after controlling for age in a sepa-
rate cohort assessed after a similar disease duration.
Speculatively, the effects of ageing on associations
between the cBF and gait and cognition may outweigh
the effects of PD in early disease, whereas ageing effects
may become secondary to disease pathology as the dis-
ease progresses. This may explain the recent associa-
tions made between the NBM and fast walking speed
in later stage PD.31 Repeating cross-sectional analyses
at a later disease point may give valuable insight to this
suggestion.
As with previous reports,26,28 we found no differ-
ences in cBF volumes in people with PD compared with
controls. A lack of between-group differences may be
because of heterogeneity of cholinergic degeneration in
early PD,17 with only a portion of early PD presumed
to have cholinergic involvement. Additionally, volumet-
ric changes may not be sensitive to very early structural
changes in the region. Indeed, degeneration of white
matter projections occurs before GM atrophy in PD,50
and NBM white matter tract integrity is more strongly
associated with cognitive performance than NBM vol-
ume in healthy individuals.51
NBM Volumes Predict Disease-Specific Gait
Decline
We wished to explore the predictive value of sub-
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FIG. 2. Correlation between sub-regional cBF volumes at baseline and change in gait per year in Parkinson’s disease. A: correlation between change in
step length and baseline posterior NBM (Ch4p) volume. B: correlation between change in step time variability and baseline posterior NBM (Ch4p) vol-
ume. C: correlation between change in swing time and baseline NBM (Ch4) volume. D: correlation between change in step time variability and baseline
NBM (Ch4) volume. Values for gait change per year were derived from the model coefficient for time, for individuals within the Parkinson’s disease
cohort.) [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 3. LMEM assessing sub-regional cBF volumes as predictors of gait change in Parkinson’s disease
Gait characteristic Predictor region Regression coefficients
β SE t P-value CI
Step length (m) Ch4p 0.0980 0.0353 2.78 0.007* (0.028, 0.169)
Ch4 0.0806 0.0494 1.63 0.107 (−0.017, 0.181)
Ch1-2 0.0407 0.0421 0.97 0.336 (−0.042, 0.125)
Step time variability (ms) Ch4p −14.466 6.027 −2.40 0.019* (−26.6, −2.57)
Ch4 −17.195 8.276 −2.08 0.041* (−34.0, −0.872)
Ch1-2 −11.376 6.979 −1.63 0.107 (−25.3, 2.42)
Step length variability (m) Ch4p −0.0043 0.0064 −0.67 0.506 (−0.017, 0.008)
Ch4 0.0005 0.0087 0.06 0.955 (−0.017, 0.018)
Ch1-2 −0.0027 0.0073 −0.37 0.712 (−0.017, 0.012)
Swing time (ms) Ch4p −27.91 14.52 −1.92 0.058 (−56.5, 1.24)
Ch4 −47.88 19.25 −2.49 0.015* (−85.8, −9.04)
Ch1-2 −16.08 16.96 −0.95 0.345 (−49.7, 18.6)
Baseline age, sex, and global gray matter volume were included as fixed effects in models. Significant predictors of changes in gait are in bold and denoted by *.
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PD gait impairment, so restricted longitudinal analyses
to the four gait characteristics that changed significantly
and more greatly than in controls. These were step
length, step time variability, step length variability, and
swing time. Of these, only step length variability
changes were not predicted by baseline NBM volumes.
Analyses controlled for both TIV and total GM vol-
ume, giving us confidence in the precision of the identi-
fied associations between the NBM and gait. All
assessments were completed “on” dopaminergic medica-
tion. Recent work has also identified an association
between NBM integrity and fast walking speed as
assessed “on”, but not “off,” dopaminergic medica-
tion.31 Speculatively, therefore, our findings may sup-
port the notion that the influence of the cholinergic
system on gait is only evident when “confounding”
effects of dopamine are accounted for through optimi-
zation of the dopaminergic system.
Step Time Variability
The relationship between baseline NBM volumes and
step time variability change is consistent with data
showing that CSF β-amyloid 1–42 (linked to NBM
atrophy in older adults32) is a predictor of step time
variability change.10 Additionally, step time variability
demonstrated disease-specific, dopa-resistant change in
the entire ICICLE-GAIT cohort over 3 years10 that was
confirmed in the participants assessed here. This char-
acteristic should therefore be considered a robust mea-
sure of gait change in PD, and the current data imply it
is cholinergically mediated.
Step Length
Step length typically responds well to L-dopa in early
disease, because it closely reflects hypokinesia, whereas
gait variability measures are not always responsive.52
The association between NBM volumes reported here
and step length may indicate that step length is not
purely dopaminergically controlled, supported by the
previously identified association between step length
and SAI.22 Step length has also been linked to the hip-
pocampus in healthy older adults,14 which is thought
to be involved in spatial navigation while walking.53 As
such, it was surprising that no relationship between
step length and volume of the hippocampal-projecting
Ch1-2 region was identified.
Swing Time
Somewhat counterintuitively, larger baseline NBM
volumes predicted greater reductions in swing time—
typically considered a gait impairment—over 3 years.
However, in PD, shortening swing time may reflect a
compensatory strategy in which the timing of steps
becomes shorter in an attempt to overcome shortening
step length, thereby preserving overall walking speed.54
Shortening step timings as a compensatory strategy is
thought to be controlled primarily by the cerebellum
acting to increase primary motor cortex activity.55 Our
findings may indicate that structurally preserved NBM
volumes reflect a greater ability to use this compensa-
tory mechanism, a suggestion supported by the known
role of acetylcholine (ACh) in compensatory
processes.56,57
The Role of Cognition
Cortical ACh is associated with cognition, specifically
executive function and attention.58 These cognitive
domains are strongly related to gait dysfunction in
PD.30 Specifically, gait characteristics within the pace
gait domain,8 including step length, have been linked to
executive function and attention whereas global cogni-
tion has been linked to gait variability.34 Additionally,
changes in fluctuating attention in early PD are
predicted by step length, step length variability, and
step time variability.6 The current study provides tenta-
tive evidence for a shared neural underpinning of gait
and cognition that may originate within the NBM.
Understanding the role of cognition in associations
between gait and the cBF requires an in-depth investiga-
tion of the effects of different cognitive domains on
both gait and imaging parameters, as well as how these
interact over time. The complexity of this warrants its
own independent investigation and would form a useful
follow-on study.
Clinical Implications
Primarily, this work aimed to further understanding
of the cholinergic underpinnings of PD gait mechanisti-
cally. However, findings may also have clinical use.
This study provides first evidence that cBF volumes can
predict gait changes in PD. As such, these volumetric
measures could be considered within a combinational
battery of clinical biomarkers of gait progression, to
monitor disease progression, and stratify patients in
clinical trials. As gait changes and falls are closely
related,5 whether NBM volumes could act as warning
markers for those more likely to experience falls war-
rants further investigation.
This study has also provided further evidence for an
association between the cortical cholinergic system and
PD gait impairment, highlighting the need for novel
therapies extending beyond the dopaminergic system.
AChE inhibitors, which act to increase available ACh,
can improve mobility measures in PD,15,52 including
gait speed and step time variability as a proxy marker
for falls risk.59,60 Overall, findings help strengthen the
case for therapeutically targeting the cholinergic system
to limit PD gait progression.
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Limitations
Some limitations should be noted. Attrition was nota-
ble at 30% over 3 years, comparable to similar studies.61
Mixed-effects models allowed use of all data and reduced
bias compared to traditional analytical approaches. Rates
of changes in gait over time may have been under-
estimated, as non-completers had greater disease severity
at baseline than completers (although the difference
between these was non-significant). Assessments were
completed in close succession (median of 3 weeks), yet
gait and imaging assessments were dissociated in time
and so correlation-based analyses were required.
Although the Ch4 region from the stereotactic atlas cor-
responds to cholinergic neurons within the NBM, the
NBM has heterogeneous cell populations, and we cannot
dismiss a contribution from these populations to findings.
The stereotactic map was generated from one post-
mortem brain, suggesting that inter-individual variability
in volumes may not be optimally considered, although
the efficient DARTEL algorithm normalized volumes in
MNI space.43 This study aimed to further our under-
standing of the relationship between the cortical choliner-
gic system and PD gait impairment. Future investigations
should also consider the involvement of subcortical cho-
linergic structures in PD gait, such as the PPN, to estab-
lish whether the cholinergic nuclei investigated here are
uniquely associated with gait in PD, as has been previ-
ously found.23 Finally, as with all volumetric measures,
cBF volumes may not directly reflect cholinergic activity,
which must be assessed through molecular imaging
targeting the cortical cholinergic system.23,24 Multi-modal
neuroimaging approaches are required to fully under-
stand the effect of cBF volume loss on cholinergic
activity.
Conclusions
In conclusion, NBM atrophy measured in PD can
predict future disease-specific gait changes. Findings
reinforce the notion that gait control in PD involves the
cortical cholinergic system, and that ACh should, there-
fore, be considered as a therapeutic target to mitigate
gait dysfunction. Considered alongside the extant litera-
ture, NBM atrophy may underpin both motor and cog-
nitive impairments. Further investigations of the
interplay between NBM volume, gait and cognition
must be considered to understand these complex
relationships.
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